News for Eyenovia, Inc. (EYEN)

Eyenovia, Inc. (EYEN) has announced significant strides in the development of its innovative Optejet User Filled Device (UFD). This device is set to revolutioni

On track for regulatory submission seeking marketing approval of the Optejet UFD in Q4 2025 NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. ( EY

Massachusetts-based Allurion Technologies Inc. (ALUR) is up over 64 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

Massachusetts-based Allurion Technologies Inc. (ALUR) is up over 64 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

Eyenovia (EYEN) stock falls as the company plans a reverse merger with Betaliq, to create an ophthalmology focused drugmaker. Read more here.

Combination, if successful, would create a new publicly-listed eye care company combining Betaliq's EyeSol® water-free drug delivery technology for glaucoma wi

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. ( EYEN) (”œEyenovia” or the ”œCompany"), an ophthalmic technology company focused on completing

Amendment provides financial flexibility to the Company by deferring all interest as well as principal redemption payments through September 2025, while reduci

**media[532715,532716]**

Eyenovia board approves 1-for-80 reverse stock split to regain Nasdaq compliance, leading to 28% share price drop post-market.

**media[515643]**

Virtual meeting scheduled for 10:00 a.m. ET on January 21st; stockholders must pre-register by 11:59 p.m. ET on January 20th NEW YORK, Jan. 15, 2025 (GLOBE

Company concurrently focused on completing development of the Gen-2 user-filled Optejet® device by 3Q 2025 while reducing spend by over 60% NEW YORK, Jan. 0

Shares of Cemtrex, Inc. CETX rose sharply in today's pre-market trading after the company posted stronger-than-expected sales for the fourth quarter, reporting ...

**media[485345]**

NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. ( EYEN) (”œEyenovia” or the ”œCompany”), an ophthalmic technology company developing and comm

**media[473619]**

Avenue Capital agrees to Company's deferral of principal and interest payments on its outstanding debt until the end of February 2025 Eyenovia continues to e

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.70%